Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smartwatch and glucose monitor team up to motivate cancer survivors

NCT ID NCT05490641

First seen Feb 16, 2026 · Last updated Jun 23, 2026 · Updated 18 times

Summary

This study tested whether showing cancer survivors real-time feedback from a continuous glucose monitor and activity tracker could motivate them to exercise more. Sixty cancer survivors at high risk for type 2 diabetes wore a Fitbit and received personalized text messages for 12 weeks. The goal was to see if this approach was feasible and could increase daily physical activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The University of Texas at Arlington

    Arlington, Texas, 76010, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Glucose-based biofeedback via continuous glucose monitor and Fitbit activity tracker

What this could lead to

If successful, this approach could help cancer survivors become more active and reduce their risk of type 2 diabetes.

What could go wrong

This is a small, early feasibility study with only 60 participants. It tests whether the method works, not whether it improves health outcomes.

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.